Skip to content
Screener

Harrow HROW Pre-Tax Income

Pre-Tax Income at other companies

AbbVie logo
AbbVieABBV
$4.28B+175%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.57M+205%
Bausch + Lomb logo
Bausch + LombBLCO
-$11M+92.5%
Opko Health logo
Opko HealthOPK
-$13.4M+91.8%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$1.35B-2,781%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-$16.09M+44.3%

Other financials

Income statement

See full
Revenue$70.7M+10.9%
Gross profit$50.4M+6.0%
Operating income-$11.0M-196%
Net income-$17.3M-446%
EPS (diluted)-$0.46-454%

Balance sheet

See full
Cash & equivalents$83.9M+58.4%
Total debt$308.4M-32.0%
Total equity$15.2M-69.4%
Total assets$416.8M+20.8%

Cash flow

See full
Operating cash flow-$9.8M
CapEx$491.0K+196%
Free cash flow-$10.2M

Valuation

See full
Market cap$1.49B+21.7%
Enterprise value$1.71B+5.7%
P/S5.4×0.0×

Profitability

See full
Gross margin73.3%-1.3pp
Operating margin-1%-7.3pp
Net margin-19.8%+18.0pp
FCF margin1.8%+1.3pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity20.3×+11.2×
Current ratio2.2×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Harrow’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055271
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
(Loss) income from operations(11,007,000)11,409,000(33,087,000)177,000
Interest expense, net(6,263,000)(6,408,000)(11,760,000)(12,956,000)
Other (expense) income, net(6,000)(6,000)
(Loss) income before income taxes(17,270,000)4,995,000(44,847,000)(12,785,000)
Income tax expense(25,000)
Net (loss) income$(17,270,000)$4,995,000$(44,872,000)$(12,785,000)
Basic net (loss) income per share of common stock$(0.46)$0.14$(1.20)$(0.35)
Diluted net (loss) income per share of common stock$(0.46)$0.13$(1.20)$(0.35)

Item 1. Financial Statements

FAQ

What is Harrow's pre-tax income?
Harrow (HROW) reported pre-tax income of -$17.27M in Q2 2026.
How has Harrow's pre-tax income changed year-over-year?
Harrow's pre-tax income decreased by 445.7% year-over-year, from $5M to -$17.27M.
What is the long-term trend for Harrow's pre-tax income?
Over 2 years (2021 to 2023), Harrow's pre-tax income has grown at a 15.2% compound annual growth rate (CAGR), from -$17.87M to -$23.71M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Harrow's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude